{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&_page=0&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&_page=0&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_metadata=all&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&_page=0&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "isPartOf" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&_page=0&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "type" : "http://purl.org/linked-data/api/vocab#ListEndpoint"}
    , "items" : [{"_about" : "http://data.parliament.uk/resources/529943", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/529943/answer", "answerText" : {"_value" : "<p>A home consultation can be offered where a claimant is unable to travel to a consultation as a result of their health condition or impairment.<\/p><p> <\/p><p>Situations where a claimant may need a home consultation can include where a person\u2019s diagnosis suggests a significant disability that may make travel extremely difficult or the claimant provides evidence from a health professional that they are unable to travel due to their health condition or impairment.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4533", "label" : {"_value" : "Biography information for Baroness Altmann"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Altmann"}
        , "dateOfAnswer" : {"_value" : "2016-07-13", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2016-07-13T15:08:42.427Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2016-06-29", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Stamp Duty Land Tax"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty\u2019s Government, further to the Written Answer by Baroness Altmann on 16 June (HL502), what provision is made for claimants suffering severe myalgic encephalomyelitis or chronic fatigue syndrome who are housebound or bedbound and who are unable to attend a face-to-face consultation.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL871"}
    , {"_about" : "http://data.parliament.uk/resources/1131898", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1131898/answer", "answerText" : {"_value" : "<p>The Department funds research via the National Institute for Health Research (NIHR). The NIHR does not itself classify any organisation in terms of charitable status or lobby group. The NIHR regards a charity as a specific type of voluntary organisation which must conform to the regulations set out in charity law particularly the Charities Act 2011. Charity is a legal status for an organisation, not a legal form or organisational structure.<\/p><p>Any organisation which considers that it can carry out high-quality clinical, applied health or social care research is likely to be eligible for Departmental, NIHR-funded research programmes, either directly or with a partner. There are specific guidance documents setting out eligibility criteria for the NIHR\u2019s programmes which include information on partnership working, funding mechanism and contractual obligations including reporting and disclosure of conflicts of interest.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4703", "label" : {"_value" : "Biography information for Baroness Barran"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Barran"}
        , "dateOfAnswer" : {"_value" : "2019-06-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-26T13:13:51.12Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "International Life Sciences Institute"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government, following the publication of the study on the International Life Sciences Institute \"Are industry-funded charities promoting \u201cadvocacy-led studies\u201d or \u201cevidence-based science\u201d?, whether they classify the International Life Sciences Institute as an industry lobby group or a scientific health charity.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL16316"}
    , {"_about" : "http://data.parliament.uk/resources/1128009", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1128009/answer", "answerText" : {"_value" : "<p>The Lightning Process (LP) is not offered as a part of the chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) standard treatments on the National Health Service. Subject to the nature of the safeguarding concerns, issues should be directed to the relevant professional regulator, should the practitioner be a member of a registered profession; the local authority (trading standards office or children\u2019s service), if false claims are being made about the effectiveness of the treatment or welfare of a child is a concern; or the police, if a crime is involved.<\/p><p>The LP involves a course of three half-days of training aiming to teach participants how to use their brain to improve their body's health.<\/p><p>A randomised controlled trial with 100 adolescents aged 12-18 was undertaken by researchers in Bristol. Participants were randomised into two groups: those who received standard CFS/ME treatment and those who received the standard treatment plus the LP.<\/p><p>Researchers found those who received the LP had better physical function, were less tired and less anxious after six months. At 12 months, they had further improvement in physical function, and improved depression scores and school attendance. This research trial had several limitations as set out in the peer reviewed journal article. This was a very small trial and so it would need to be repeated in a much larger group to demonstrate more generalisable findings. Participants were not blinded so their self-reported outcomes might have been biased, for example participants may have been more likely to report positive outcomes because they knew they were getting additional therapy in the LP group. Of all those eligible to participate in the trial, fewer than 30% agreed to take part. Participants in the trial did not have any serious adverse events attributable to either LP or usual care. LP therapy was given in addition to the usual CFS/ME care as a no-treatment control group was not deemed ethical, therefore it cannot be suggested as a replacement for current specialised medical care.<\/p><p>Independent ethical review ensures that participant safety is at the centre of all research. In the United Kingdom, review by an ethics committee is one of a series of safeguards intended to protect the people taking part in the research. The operating procedure for trials in the UK has inbuilt safeguards designed to protect patients from harm in the event an intervention is ineffective or potentially harmful. Participants are free to withdraw from a study at any time.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-06-05", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-05T16:40:17.41Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-05-21", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Medical Treatments: Children"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what processes are in place to safeguard children with chronic fatigue syndrome and other disorders whose parents have enrolled them on Lightning Process courses; and what evaluation has been undertaken of the (1) benefits, and (2) harms, to those children who have participated in such courses.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL15894"}
    , {"_about" : "http://data.parliament.uk/resources/1131897", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1131897/answer", "answerText" : {"_value" : "<p>The appointment is subject to the approval process which governs the Civil Service Commission Recruitment Principles. An announcement will be made once that process has concluded.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-06-26", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-06-26T12:11:36.557Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-06-12", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Food Standards Agency: Public Appointments"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government when they intend to approve the appointment of a Chief Executive for the Food Standards Agency; and what has been the cause of the delay.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL16315"}
    , {"_about" : "http://data.parliament.uk/resources/1135740", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135740/answer", "answerText" : {"_value" : "<p>A meeting was held by the Global Advisory Committee on Vaccine Safety (GACVS) on 5 to 6 June 2019. However, the Medicines and Healthcare products Regulatory Agency is not aware of any formal review of human papillomavirus vaccine safety published by GACVS in 2019.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:24:58.8Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Human Papillomavirus: Vaccination"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government whether they will place a copy of the World Health Organisation Global Advisory Committee on Vaccine Safety 2019 review of HPV vaccine safety in the Library of the House.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL16833"}
    , {"_about" : "http://data.parliament.uk/resources/1135741", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135741/answer", "answerText" : {"_value" : "<p>At its meeting in February 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recommended that the product information for mefloquine (Lariam) be amended to state that neuropsychiatric adverse reactions may persist for months, or longer, even after discontinuation of the drug. The Medicines and Healthcare products Regulatory Agency (MHRA) accepted the recommendations and implemented the advice of the PRAC, which is reflected in the United Kingdom product information for mefloquine. In addition, the MHRA has since taken further action to ensure that these risks are adequately conveyed to UK prescribers and patients in the form of improved checklists for healthcare professionals and a patient alert card.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-07-10", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-10T15:26:45.817Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mefloquine"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the European Medicines Agency Pharmacovigilance Risk Assessment Committee\u2019s 2014 report on the toxicity of mefloquine (Larium).", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL16834"}
    , {"_about" : "http://data.parliament.uk/resources/1135743", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1135743/answer", "answerText" : {"_value" : "<p>The Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment has considered the evidence on the potential effects of chlorinated and non-chlorinated phosphate flame retardants from all exposure sources, in general. The Committee is preparing a statement on phosphate-based flame retardants and the potential for neurodevelopmental toxicity. It is expected that the statement will be published in summer 2019.<\/p><p>Chlorinated organophosphorous flame retardants are regulated under the European Union REACH (Restriction, Evaluation, Authorisation and Restriction of Chemicals) regime. The United Kingdom has been proactive in supporting the regulation of flame retardants through REACH. The European Chemicals Agency has announced an intention to restrict a number of chlorinated flame retardants. It is expected that the restriction proposal will be submitted in July 2019, followed by a public consultation.<\/p><p> <\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4019", "label" : {"_value" : "Biography information for Baroness Blackwood of North Oxford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Blackwood of North Oxford"}
        , "dateOfAnswer" : {"_value" : "2019-07-15", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-07-15T10:24:38.953Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2019-07-01", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Mattresses: Fire Resistant Materials"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what assessment they have made of the risks to the neurological development of (1) foetuses, and (2) new-born children, of exposure to polyurethane mattresses treated with chlorinated phosphate flame retardants.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL16836"}
    , {"_about" : "http://data.parliament.uk/resources/749951", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/749951/answer", "answerText" : {"_value" : "<p>The Health and Safety Executive (HSE) will not be attending the International Aircraft Cabin Air Conference at Imperial College, London in September 2017. HSE works with the Civil Aviation Authority (CAA) to regulate health and safety at work in the aviation industry. This operates through a memorandum of understanding and associated guidance document CAP 1484 (see documents attached).<\/p><p>CAP 1484 states that by agreement CAA regulates health and safety on board aircraft and advises on the health implications of exposure to hazardous substances on crew and passengers. CAA is the most appropriate regulatory attendee and HSE will seek information and updates on such issues through its regular contacts with CAA.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3349", "label" : {"_value" : "Biography information for Baroness Buscombe"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Buscombe"}
        , "attachment" : [{"_about" : "http://data.parliament.uk/resources/749951/answer/attachment/1", "fileName" : {"_value" : "HL636 - Associated Guidance Document CAP 1484 (March 2017).pdf"}
          , "title" : "Associated Guidance Document CAP 1484"}
        , {"_about" : "http://data.parliament.uk/resources/749951/answer/attachment/2", "fileName" : {"_value" : "HL636 - HSE CAA Memorandum of Understanding.pdf"}
          , "title" : "HSE CAA Memorandum of Understanding"}
        ], "dateOfAnswer" : {"_value" : "2017-07-18", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-18T13:18:23.34Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2017-07-10", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "NHS: Listed Buildings"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government whether the Health and Safety Executive will send a representative to the International Aircraft Cabin Air Conference at Imperial College, London in September; and if not, why not.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL636"}
    , {"_about" : "http://data.parliament.uk/resources/1140485", "AnsweringBody" : [{"_value" : "Department for Work and Pensions"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1140485/answer", "answerText" : {"_value" : "<p>The department is committed to ensuring claimants receive high quality assessments. We set our assessment providers challenging targets and monitor performance closely against a range of measures including through independent audit to improve accuracy and decision making. Contractual remedies are in place if assessment providers fail to deliver against the service standards.<\/p><p>Contractual remedies for underperformance against a range of service levels are recovered through service credit mechanisms and through deductions of payments (a \u2018No Pay\u2019 mechanism). The extent of underperformance and application of related mechanisms varies significantly and the regularity of such remedies should not be seen as a measure of overall performance.<\/p><p>In relation to the HDAS contract covering Work Capability Assessments, service credits (the contractual remedy for SC1 \u2013 Quality) have been applied in 12 out of the 14 months from June 2018 to July 2019 (the date of the most recent statistical information available).<\/p><p>In relation to the Personal Independence Payment contracts, \u201cNo Pay\u201d (the contractual remedy for SC1 \u2013 Quality) has been applied in one or more Lots in each month from June 18 to June 19 (the date of the most recent statistical information available).<\/p><p>Below is the breakdown of the totals by Lot:<\/p><p>Lot 1 \u2013 No pay was applied to SC1 in 8 of those months<\/p><p>Lot 2 \u2013 No pay was applied to SC1 in 5 of those months<\/p><p>Lot 3 \u2013 No pay was applied to SC1 in 11 of those months.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4174", "label" : {"_value" : "Biography information for Baroness Stedman-Scott"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Stedman-Scott"}
        , "dateOfAnswer" : {"_value" : "2019-08-12", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2019-08-12T15:58:29.597Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "29"}
      , "answeringDeptShortName" : {"_value" : "Work and Pensions"}
      , "answeringDeptSortName" : {"_value" : "Work and Pensions"}
      , "date" : {"_value" : "2019-07-18", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Social Security Benefits: Medical Examinations"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "To ask Her Majesty's Government what controls and penalties are in place to ensure that providers of medical assessors for social security benefits maintain high standards of accuracy and integrity; and on how many occasions any such controls or penalties have been used since June 2018.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL17318"}
    , {"_about" : "http://data.parliament.uk/resources/746633", "AnsweringBody" : [{"_value" : "Home Office"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/746633/answer", "answerText" : {"_value" : "<p>Public safety is a priority for Government. There are a range of measures in place across a number of Government departments to ensure the effectiveness and safety of flame retardant materials.<\/p><p> <\/p><p>The Department for Business, Energy and Industrial Strategy is responsible for product safety legislation, which requires products to be safe when they are placed on the market.<\/p><p> <\/p><p>The Department for the Environment, Food and Rural Affairs has responsibility for ensuring the safety of chemicals, including those used as flame retardants.<\/p><p> <\/p><p>The Health and Safety Executive oversees the EU regulations concerning the Registration, Evaluation, Authorisation and restriction of Chemicals (known as REACH). This has several aims, including providing a high level of protection of human health and the environment from the use of chemicals.<\/p><p> <\/p><p>Lead responsibility for the safety and effectiveness of flame retardant chemicals will rest with the Department responsible for any legislation specifying their usage.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4311", "label" : {"_value" : "Biography information for Baroness Williams of Trafford"}
        }
        , "answeringMemberPrinted" : {"_value" : "Baroness Williams of Trafford"}
        , "dateOfAnswer" : {"_value" : "2017-07-13", "_datatype" : "dateTime"}
        , "groupedQuestionUIN" : {"_value" : "HL265"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2017-07-13T14:40:39.827Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "1"}
      , "answeringDeptShortName" : {"_value" : "Home Office"}
      , "answeringDeptSortName" : {"_value" : "Home Office"}
      , "date" : {"_value" : "2017-06-29", "_datatype" : "dateTime"}
      , "houseId" : {"_value" : "2"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"}
      }
      ], "questionText" : "Her Majesty's Government what measures they are taking to ensure that flame retardant materials used in homes, offices and public spaces both (1) prevent fires, and (2) are non-toxic, (a) in normal use, (b) during fires, and (c) for disposal or recycling at the end of life of items, such as furniture, foam mattresses, electronic goods and building insulation which contain such materials.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1861", "label" : {"_value" : "Biography information for The Countess of Mar"}
      }
      , "tablingMemberPrinted" : [{"_value" : "The Countess of Mar"}
      ], "uin" : "HL264"}
    ], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?tablingMember.label=Biography%20information%20for%20The%20Countess%20of%20Mar&_page=1&min-answer.questionFirstAnswered.=2016-07-13T15:08:42.427Z&_sort=tablingMemberConstituency,answer.answeringMemberPrinted,-answer.isMinisterialCorrection,-tablingMemberPrinted,answeringDeptSortName", "page" : 0, "startIndex" : 1, "totalResults" : 154, "type" : "http://purl.org/linked-data/api/vocab#Page"}
}